Celltrion Pharm, 3Q Sales 103.8 Billion KRW... Operating Profit 13.5 Billion KRW

Celltrion Pharm CI (Photo by Celltrion Pharm)

[Asia Economy Reporter Chunhee Lee] Celltrion Pharm achieved its highest-ever sales in the third quarter of this year with 103.8 billion KRW. Operating profit also recorded an all-time high at 13.5 billion KRW.

Celltrion Pharm announced on the 14th that its third-quarter sales this year amounted to 103.79511 billion KRW, operating profit was 13.46446 billion KRW, and net profit was 7.95203 billion KRW. Compared to the same period last year, sales increased by 14.2% and operating profit by 3.5%, achieving the highest sales and operating profit for any third quarter in history. However, net profit decreased by 10.9%.

On a cumulative basis for this year, sales grew by 8.3% to 297.94295 billion KRW compared to last year. Meanwhile, operating profit was 32.08391 billion KRW and net profit was 19.76776 billion KRW, down 18.3% and 32.9% respectively from the previous year.

The company explained that both the chemical pharmaceuticals and biopharmaceuticals divisions showed balanced growth in sales. In the domestic chemical pharmaceuticals sector, the liver medicine ‘Godeks Capsule,’ which recently received a final decision to maintain reimbursement in the recent reimbursement adequacy reassessment, led the performance with sales of approximately 17.4 billion KRW. Along with this, diabetes treatments ‘Nesina,’ ‘Actos,’ and hypertension treatment ‘Idalbi’ posted stable sales, driving growth.

In the biopharmaceuticals division, autoimmune disease treatment ‘Remsima,’ breast and stomach cancer treatment ‘Herzuma,’ and blood cancer treatment ‘Truxima’ recorded sales of about 18 billion KRW, achieving approximately 25% growth compared to the same period last year. The newly launched autoimmune disease treatment ‘Uplima’ also began full-scale sales this year, expected to provide additional growth momentum for the biopharmaceuticals business in the future.

Celltrion Pharm plans to focus on its existing business while accelerating the launch and market establishment of new products. In particular, it will speed up the launch of the anticancer antibody biosimilar ‘Vegzelma,’ which recently obtained domestic product approval, and strengthen marketing to expand sales of the Alzheimer’s dementia treatment ‘Donerion Patch.’

A Celltrion Pharm official said, “As chemical and bio products continue steady growth and new products enter the market smoothly, we expect the growth trend to continue for the time being. We will strengthen marketing based on an expanded portfolio as well as pipeline enhancement to continue expanding market share and growth.”

This content was produced with the assistance of AI translation services.